

**R&D Day**

December 05, 2019

London, UK

[Read the media release](#)

[Download the agenda \(PDF 0.1 MB\)](#)

[Download the presentation \(PDF 8.1 MB\)](#)

**Novartis enters into agreement to acquire The Medicines Company**

November 25, 2019

Basel, Switzerland

[Read the media release](#)

[Read the presentation transcript](#)

[Download the podcast \(MP3 26 MB\)](#)

[Download the presentation \(PDF 0.6 MB\)](#)

**Third quarter results 2019**

October 22, 2019

Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) | [Deutsch \(PDF 0.2 MB\)](#) | [Français \(PDF 0.3 MB\)](#)

[Interim financial report \(PDF 0.8 MB\)](#)

---

[Read the presentation transcript](#)

[Download the presentation \(PDF 2.3 MB\)](#)

**Beovu® FDA Approval**

October 08, 2019

Basel, Switzerland

[Read the media release](#)

[Download the presentation \(PDF 1.4 MB\)](#)

[Download the podcast \(MP3 22 MB\)](#)

**Kisqali® MONALEESA-3 ESMO Data Investor Call**

October 01, 2019  
Basel, Switzerland

[Download the podcast \(MP3 14 MB\)](#)

[Download the presentation \(PDF 1.8 MB\)](#)

### **Ofatumumab (OMB157) ECTRIMS Data Investor Call**

September 16, 2019  
Basel, Switzerland

[Download the podcast \(MP3 26 MB\)](#)

[Download the presentation \(PDF 1.1 MB\)](#)

### **ESG Investor Event**

September 09, 2019  
London, UK

[Download the podcast \(MP3 40 MB\)](#)

[Download the presentation \(PDF 4.8 MB\)](#)

### **Zolgensma® Update**

August 07, 2019

[Read the media release \(PDF 0.4 MB\)](#)

[Download the podcast \(MP3 16 MB\)](#)

### **Second quarter results 2019**

July 18, 2019  
Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) | [Deutsch \(PDF 0.1 MB\)](#) | [Français \(PDF 0.2 MB\)](#)

[Interim financial report \(PDF 0.6 MB\)](#)

---

[Read the presentation transcript](#)

[Download the podcast \(MP3 41 MB\)](#)

[Download the presentation \(PDF 2.2 MB\)](#)

### **ASCO Investor Event**

June 02, 2019  
Chicago, USA

[Download the presentation \(PDF 0.8 MB\)](#)

## **Zolgensma® and Piqray® US FDA Approvals**

May 27, 2019

Read the media releases:

[AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy \(SMA\)](#)

[AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families](#)

[FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer](#)

[Zolgensma US prescribing information \(PDF 0.3 MB\)](#)

[Download the presentation \(PDF 0.8 MB\)](#)

[Download the podcast \(MP3 22 MB\)](#)

## **Meet Novartis Management investor event**

May 23, 2019

Boston, USA

[Read the media release](#)

[Download the presentation \(PDF 7.8 MB\)](#)

[Download the agenda \(PDF 0.1 MB\)](#)

## **Novartis enters into agreement to acquire Xiidra®**

May 09, 2019

[Read the media release](#)

[Download the podcast \(MP3 18 MB\)](#)

[Download the presentation \(PDF 0.8 MB\)](#)

## **Zolgensma AAN Data Investor Call**

May 08, 2019

Philadelphia, USA

[Download the podcast \(MP3 25 MB\)](#)

[Download the presentation \(PDF 1.0 MB\)](#)

## **First quarter results 2019**

April 24, 2019

Basel, Switzerland

Media release:

[English \(PDF 0.5 MB\)](#) | [Deutsch \(PDF 0.4 MB\)](#) | [Français \(PDF 0.8 MB\)](#)

[Interim financial report \(PDF 0.5 MB\)](#)

---

[Read the presentation transcript](#)

[Download the podcast \(MP3 41 MB\)](#)

[Download the presentation \(PDF 1.4 MB\)](#)

### **2017/2018 Results for Continuing Operations**

April 24, 2019

[Download the presentation \(PDF 0.4 MB\)](#)

### **Mayzent FDA Approval Investor Call**

March 27, 2019

Basel, Switzerland

[Read the media release](#)

[Download the presentation \(PDF 0.9 MB\)](#)

[Download the podcast \(MP3 23 MB\)](#)

### **Updated Alcon 20-F filed with the SEC**

March 22, 2019

[Download the updated Alcon 20-F \(PDF 2.0 MB\)](#)

[SEC filing](#)

### **Annual General Meeting**

February 28, 2019

Basel, Switzerland

[Visit the Annual General Meeting section](#)

### **Fourth Quarter and Full Year Results 2018 and Annual Report 2018 publication**

January 30, 2019

Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) | [Deutsch \(PDF 0.1 MB\)](#) | [Français \(PDF 0.2 MB\)](#)

[Condensed financial report \(PDF 0.6 MB\)](#)

---

[Read the presentation transcript](#)

[Download the podcast \(MP3 51 MB\)](#)

[Download the presentation \(PDF 3.4 MB\)](#)

---

[Download the Annual Report 2018 \(PDF 3.8 MB\)](#)

## **J.P. Morgan Healthcare Conference**

January 07, 2019

San Francisco, USA

[Download the presentation \(PDF 1.9 MB\)](#)

---

**Source URL:** <https://www.novartis.com/node/63011>

### **List of links present in page**

- <https://www.novartis.com/node/63011>
- <https://www.novartis.com/news/media-releases/novartis-expects-sustain-long-term-growth-robust-pipeline-25-potential-blockbusters-highlighted-rd-day>
- [https://www.novartis.com/sites/novartis\\_com/files/2019-r-d-day-investor-agenda.pdf](https://www.novartis.com/sites/novartis_com/files/2019-r-d-day-investor-agenda.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf)
- <https://www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global-cause-death>
- <https://www.novartis.com/investors/event-calendar/novartis-enters-agreement-acquire-medicines-company>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/novartis-agreement-acquire-medicines-company-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/novartis-agreement-acquire-medicines-company-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-agreement-acquire-medicines-company-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-agreement-acquire-medicines-company-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2019-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2019-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2019-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2019-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2019-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2019-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-10-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2019-10-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q3-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2019-ir-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2019-ir-presentation.pdf)
- <https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept>
- [https://www.novartis.com/sites/novartis\\_com/files/2019-10-novartis-beovu-fda-approval-investor-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-10-novartis-beovu-fda-approval-investor-call-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-10-novartis-beovu-fda-approval-investor-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-10-novartis-beovu-fda-approval-investor-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-10-novartis-esmo-investor-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-10-novartis-esmo-investor-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-10-novartis-esmo-investor-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-10-novartis-esmo-investor-call-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-09-novartis-ectrims-investor-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-09-novartis-ectrims-investor-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-09-novartis-ectrims-investor-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-09-novartis-ectrims-investor-call-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-09-esg-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-09-esg-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-09-esg-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-09-esg-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/zolgensma-update-media-release-august-2019.pdf](https://www.novartis.com/sites/novartis_com/files/zolgensma-update-media-release-august-2019.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/zolgensma-update-recording.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/zolgensma-update-recording.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2019-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2019-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2019-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2019-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2019-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2019-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-07-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2019-07-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q2-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/q2-2019-ir-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/q2-2019-ir-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2019-ir-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2019-ir-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-06-novartis-asco-investor-event-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-06-novartis-asco-investor-event-presentation.pdf)

- <https://www.novartis.com/news/media-releases/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma>
- <https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families>
- <https://www.novartis.com/news/media-releases/fda-approves-novartis-piqray-first-and-only-treatment-specifically-patients-pik3ca-mutation-hrher2-advanced-breast-cancer>
- <https://www.novartis.us/sites/www.novartis.us/files/zolgensma.pdf>
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.mp3)
- <https://www.novartis.com/news/media-releases/novartis-highlights-company-transformation-catalyst-rich-pipeline-and-strong-progress-strategy-meet-novartis-management-investor-event>
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-meet-novartis-management-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-meet-novartis-management-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-meet-the-management-agenda.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-meet-the-management-agenda.pdf)
- <https://www.novartis.com/news/media-releases/novartis-acquire-xiidra-expanding-front-eye-portfolio-and-strengthening-leadership-eye-care>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-05-novartis-xiidra-ir-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-05-novartis-xiidra-ir-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-novartis-xiidra-ir-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-novartis-xiidra-ir-call-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-05-novartis-avexis-aan-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-05-novartis-avexis-aan-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-novartis-avexis-aan-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-novartis-avexis-aan-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2019-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2019-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2019-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2019-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2019-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2019-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-04-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2019-04-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q1-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/q1-2019-ir-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/q1-2019-ir-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2019-ir-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2019-ir-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-2017-2018-results-continuing-operations.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-2017-2018-results-continuing-operations.pdf)
- <https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease>
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-mayzent-fda-approval-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-mayzent-fda-approval-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/novartis-mayzent-fda-approval-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/novartis-mayzent-fda-approval-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/alcon-20f-filing-2019.pdf](https://www.novartis.com/sites/novartis_com/files/alcon-20f-filing-2019.pdf)
- <https://www.sec.gov/Archives/edgar/data/1167379/000104746919001507/0001047469-19-001507-index.htm>
- <https://www.novartis.com/investors/shareholder-information/annual-general-meeting>
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2018-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2018-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2018-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2018-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2018-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2018-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-01-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2019-01-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2018-q4-and-full-year-results-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-08/q4-2018-ir-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-08/q4-2018-ir-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2018-ir-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2018-ir-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-annual-report-2018-en.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2018-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-novartis-jpmorgan-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-novartis-jpmorgan-presentation.pdf)
- <https://www.novartis.com/node/63011/printable/print>
- <https://www.novartis.com/node/63011/printable/pdf>